Skip to content
← Full study record

NCT00924040 · MORE INFO

Limitations, agreements, and source contact

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia · Source last updated 2015-10-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
The study of BL22 has expired and MedImmune, the sponsor, is not interested in producing any new supply. All data has been analyzed and reviewed. All patients have been taken off study.
point Of Contact
email
kreitman@mail.nih.gov
organization
National Cancer Institute, National Institutes of Health
phone
301-496-6947
title
Robert J. Kreitman, M.D.
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
The study of BL22 has expired and MedImmune, the sponsor, is not interested in producing any new supply. All data has been analyzed and reviewed. All patients have been taken off study.
point Of Contact
email
kreitman@mail.nih.gov
organization
National Cancer Institute, National Institutes of Health
phone
301-496-6947
title
Robert J. Kreitman, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice